Presentation is loading. Please wait.

Presentation is loading. Please wait.

Serum vs FNA:.

Published byKelley Stevens Modified over 6 years ago

Similar presentations

Presentation on theme: "Serum vs FNA:."— Presentation transcript:

1 Serum vs FNA:

2 Activity Goals

3 Liquid Biopsy in Lung Cancer

4 Applications of Liquid Biopsy

5 Meta-Analysis of Blood vs Tissue Biopsy for EGFR Mutations

6 Genotyping Methodologies ctDNA and cfDNA

7 Questions Clinicians Should Be Asking About Liquid Biopsy Assays

8 Case Study Discussion

9 Guidelines for Biomarker Testing

10 Case Discussion (cont)

11 EGFR Resistance and T790M

12 AURA: Osimertinib (AZD9291) in Treatment-Naïve EGFR-Mutated NSCLC

13 Plasma Testing for T790M Has Good Sensitivity and Likely Good Specificity

14 TIGER-X: Phase 1/2 Study of Rociletinib in Advanced NSCLC

15 Concordance of Plasma and Tissue Biopsy

16 Conclusions and Clinical Pearls

17

18

Download ppt "Serum vs FNA:."

Similar presentations

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
AZD6244 Detection of BRAF Mutations in Tumour and Serum of Patients with Advanced Melanoma Dr Ruth Board CMGS Spring Scientific Conference March 26 th.

AZD6244 Detection of BRAF Mutations in Tumour and Serum of Patients with Advanced Melanoma Dr Ruth Board CMGS Spring Scientific Conference March 26 th.
The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.

The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.
A B Supplementary Figure S1. T790M CTC PointMan genotyping assay. (A) Test characteristics of PointMan CTC T790M genotyping assay. The assay was validated.

A B Supplementary Figure S1. T790M CTC PointMan genotyping assay. (A) Test characteristics of PointMan CTC T790M genotyping assay. The assay was validated.
May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.

May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.
CtDNA NGS testing identified a high-level MET amplification (copy number of 53.6 in circulation) (Figure 1A). The test was repeated on a second tube of.

CtDNA NGS testing identified a high-level MET amplification (copy number of 53.6 in circulation) (Figure 1A). The test was repeated on a second tube of.
Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.

Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.
Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.

Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.
Big Data in Genomics, Diagnostics, and Precision Medicine

Big Data in Genomics, Diagnostics, and Precision Medicine
Drug Development 2017 ctDNA: Tool of the Future?

Drug Development 2017 ctDNA: Tool of the Future?
Plasma Droplet Digital PCR for Detection of EGFR and KRAS Mutations in Patients With Advanced Nonsquamous NSCLC Slideset on: Sacher AG, Paweletz C, Dahlberg.

Plasma Droplet Digital PCR for Detection of EGFR and KRAS Mutations in Patients With Advanced Nonsquamous NSCLC Slideset on: Sacher AG, Paweletz C, Dahlberg.
Fig 1A. Patient enrollment flow chart

Fig 1A. Patient enrollment flow chart
Patient Case 1 Patient Case 1: PET/CT Scan.

Patient Case 1 Patient Case 1: PET/CT Scan.
Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.
Challenges in RAS Wild-Type mCRC

Challenges in RAS Wild-Type mCRC
Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.

The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.
Fundamental Concepts in the Diagnosis of Advanced NSCLC

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Similar presentations

Ads by Google